ICU Medical (ICUI) Q4 2016 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2016 earnings summary
6 Nov, 2026Executive summary
FY16 delivered record revenue, cash flow and earnings; the February 2017 Hospira Infusion Systems (HIS) acquisition creates a full-line infusion business and addresses dependence on a major OEM customer.
Near-term results may be less predictable during the HIS carve-out and integration; short-term outperformance is not expected, with longer-term value tied to operational improvements and broader distribution.
Financial highlights
FY16 revenue was $379.4M vs. $341.7M in FY15; operating income was $82.9M vs. $68.6M; net income was $63.1M vs. $45.0M.
Diluted EPS was $3.66 vs. $2.73; operating cash flow was $89.9M vs. $64.2M.
Gross margin was 53.1% vs. 52.9%; FY16 included a $7.6M discrete tax benefit from early adoption of ASU 2016-09.
Restructuring and strategic transaction expense was $15.3M, including $14.3M of transaction costs; R&D expense declined to $13.0M from $15.7M.
Outlook and guidance
Legacy-business 2017 capital expenditures estimated at $18M-$20M; January 2017 Mexico plant expansion completed, with further investment planned in manufacturing equipment and IT.
HIS integration expected to disrupt near-term predictability; carve-out challenges and performance depend on integration, operational improvements and successful execution.
Planned workforce reduction is expected to incur $3.8M-$4.2M in charges in H1 2017, primarily severance, with most payments expected by Q3 2017 end.
Existing cash and anticipated operating cash flows were expected to fund operations for the next 12 months; post-acquisition cash balance was approximately $270M.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020